Anthim

Active Ingredient(s): Obiltoxaximab
FDA Approved: * March 18, 2016
Pharm Company: * ELUSYS THERAPEUTICS INC
Category: Antibiotics

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Anthim Overview

Obiltoxaximab (ETI-204, trade name Anthim) is a monoclonal antibody designed for the treatment of exposure to Bacillus anthracis spores (etiologic agent of anthrax).[1] This drug was developed by Elusys Therapeutics, Inc. References ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Obiltoxaximab, American Medical Association. vteMonoclonal antibodies for infectious disease and toxinsFungal ("-fung-")Human ("-fungu-") Efungumab† Viral ("-v(i)[r]-")H...

Read more Anthim Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Obiltoxaximab

Recent Anthim Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

NDC Database Records for Anthim: (1 result)

Sorted by National Drug Code

• 69604-204 Anthim 100 mg/ml Intravenous Solution by Elusys Therapeutics, Inc.

Other drugs which contain Obiltoxaximab or a similar ingredient: (1 result)

• OBILTOXAXIMAB